Belgium Pharmaceuticals and Healthcare Report Q3 2014

  • June 2014
  • -
  • Business Monitor International
  • -
  • 125 pages

Includes 3 FREE quarterly updates
Belgium continues to attract the attention of multinational firms as a European hub for clinical trials, new
drug development and niche research. However, a highly developed pharmaceutical manufacturing industry
is increasingly threatened by cheaper suppliers from Eastern Europe and Asia. Even though per
capita spending on pharmaceuticals is relatively high, it is subjected to continual downward pressure, which
translates into growth opportunities for generic drugs. The increased uptake of generic drugs will reduce
costs for governments, out-of-pocket payers and insurance companies, which is increasingly important as
developed states reform their healthcare systems over the medium term. Prescribers' brand loyalty, pay-todelay
deals, the near-universal unpopularity of commodity generics and a lack of perfect competition in the
pharmaceutical sector, however, constitute key impediments to further generic expansion.




Headline Expenditure Projections


- Pharmaceuticals: EUR5.79bn (USD7.64bn) in 2013 to EUR5.68bn (USD7.61bn) in 2014; -2.0% in
local currency terms and -0.5% in US dollar terms. Local currency forecast slightly lower than in
Q214.
- Healthcare: EUR41.79bn (USD55.17bn) in 2013 to EUR42.76bn (USD57.29bn) in 2014; +2.3% in local
currency terms and 3.8% in US dollar terms. Local currency forecast higher than in Q214.

Table Of Contents

Belgium Pharmaceuticals and Healthcare Report Q3 2014
BMI Industry View ... 7
SWOT .. 10
Political . 12
Economic ... 13
Industry Forecast .. 14
Pharmaceutical Market Forecast 14
Table: Pharmaceutical Sales, Historical Data And Forecasts (Belgium 2010-2018) 15
Healthcare Market Forecast .. 16
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Belgium 2010-2018) . 17
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Belgium 2010-2018) . . 18
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Belgium 2010-2018) . . 18
Prescription Drug Market Forecast 19
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Belgium 2010-2018) . 21
Patented Drug Market Forecast . 22
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Belgium 2010-2018) . . 23
Generic Drug Market Forecast .. 24
Table: Generic Companies By Market Share, 2010 . 26
Table: Generics Drug Market Indicators, Historical Data And Forecasts (Belgium 2010-2018) . . 28
OTC Medicine Market Forecast . 29
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Belgium 2010-2018) . 30
Pharmaceutical Trade Forecast . 31
Table: Pharmaceutical Trade Data And Forecasts (Belgium 2012-2018) . . 33
Table: Pharmaceutical Trade Data And Forecasts local currency (Belgium 2012-2018) . 33
Other Healthcare Data . 34
Key Risks To BMI's Forecast Scenario . 35
Macroeconomic Forecasts ... 36
Economic Analysis ... 36
Table: Belgium - Economic Activity . . 39
Industry Risk Reward Ratings .. 40
Western Europe Risk/Reward Ratings .. 40
Belgium Risk/Reward Ratings 45
Rewards ... 45
Risks 45
Market Overview ... 47
Industry Trends And Developments 49
Epidemiology 49
Public Health Developments 50
Healthcare Sector .. 51
Healthcare Insurance .. 52
Healthcare Financing . 53
Medical Tourism 54
Research And Development .. 55
Table: RandD Investment By Chemical and Life Science Industries, 2005-2010 . . 55
Clinical Trials ... 59
Regulatory Development .. 61
Pharmaceutical Advertising . 62
Regulatory Developments 62
Intellectual Property Issues .. 63
Pricing Regime .. 64
Reimbursement Regime ... 65
Table: Reimbursements By Category, 2009 67
Table: Price Build-Up For OTC Medicines 69
Competitive Landscape 70
Pharmaceutical Sector 70
Recent Company Developments 71
Pharmaceutical Distribution 74
Table: Members Of AnGR, 2011 74
Pharmaceutical Retail Sector ... 75
Table: Members Of OPHACO, 2011 . 76
Company Profile 78
UCB Pharma .. 78
Solvay (Abbott) ... 86
Janssen Pharmaceutica 89
Omega Pharma ... 92
Galapagos (GSK) 96
GlaxoSmithKline ... 102
Pfizer .. 105
Novartis ... 108
Sanofi .. 110
Merck and Co .. 113
Demographic Forecast ... 115
Table: Belgium's Population By Age Group, 1990-2020 ('000) 116
Table: Belgium's Population By Age Group, 1990-2020 (% of total) 117
Table: Belgium's Key Population Ratios, 1990-2020 . 118
Table: Belgium's Rural And Urban Population, 1990-2020 118
Glossary ... 119
Methodology 121
Pharmaceutical Expenditure Forecast Model 121
Healthcare Expenditure Forecast Model ... 121
Notes On Methodology .. 122
Risk/Reward Ratings Methodology .. 123
Ratings Overview . 124
Table: Pharmaceutical Risk/Reward Ratings Indicators . 124
Indicator Weightings 125

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: Alzheimer’s Disease - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: Alzheimer’s Disease - Global Drug Forecast and Market Analysis to 2023

  • $ 10 995
  • Industry report
  • February 2015
  • by Global Data

PharmaPoint: Alzheimer’s Disease - Global Drug Forecast and Market Analysis to 2023 Summary Alzheimer’s Disease (AD) is a progressive neurodegenerative disease that is characterized by memory loss, ...

Healthcare-Acquired Infection: Devices, Pharmaceuticals, and Environmental Products

Healthcare-Acquired Infection: Devices, Pharmaceuticals, and Environmental Products

  • $ 6 650
  • Industry report
  • May 2015
  • by BCC Research

This BCC Research study provides an in-depth analysis and forecast of selected areas of the global healthcare acquired infections (HAI) market. The report offers forecasts by treatment segment and type ...

Working Capital Management in the North American and European Pharmaceutical Industry : Optimization is the Key to Working Capital Efficiency

Working Capital Management in the North American and European Pharmaceutical Industry : Optimization is the Key to Working Capital Efficiency

  • $ 6 000
  • Industry report
  • April 2015
  • by Frost & Sullivan

Executive Summary Need for Effective Working Capital Management •Decreasing profitability •Fizzling innovation model •Access to new markets •Price premium pressure Key Trends •The analysis of ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.